Elagolix + Placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Uterine Fibroids
Conditions
Uterine Fibroids
Trial Timeline
Apr 12, 2019 → Apr 28, 2021
NCT ID
NCT03886220About Elagolix + Placebo
Elagolix + Placebo is a approved stage product being developed by AbbVie for Uterine Fibroids. The current trial status is completed. This product is registered under clinical trial identifier NCT03886220. Target conditions include Uterine Fibroids.
What happened to similar drugs?
3 of 17 similar drugs in Uterine Fibroids were approved
Approved (3) Terminated (7) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03951077 | Phase 2 | Completed |
| NCT03886220 | Approved | Completed |
| NCT00619866 | Phase 2 | Completed |
Competing Products
20 competing products in Uterine Fibroids